Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Total Practice Management

Neither a doctor nor a teaching hospital

Research payments

$3,057,666

1,237 payments

Through program year 2025, Total Practice Management is reported as receiving $3,057,666 in research payments, across 1,237 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $672,000 372
2024 Research $1,145,155 576
2023 Research $653,444 173
2022 Research $364,556 72
2021 Research $213,426 40
2020 Research $9,085 4

Breakdown

Who paid Research payments · program years 2020–2025
  1. Bayer HealthCare Pharmaceuticals Inc. $1,351,703 774 payments
  2. Regeneron Pharmaceuticals, Inc. $528,497 234 payments
  3. Alexion Pharmaceuticals, Inc. $332,758 6 payments
  4. Janssen Research & Development, LLC $279,657 103 payments
  5. Genentech, Inc. $277,544 44 payments
  6. Kyowa Kirin, Inc. $113,181 48 payments
  7. Oyster Point Pharma, Inc. $113,016 21 payments
  8. Amgen Inc. $30,537 3 payments
  9. Novartis Pharmaceuticals Corporation $21,468 1 payment
  10. F. Hoffmann-La Roche AG $9,305 3 payments
Studies the money was for Research payments · program years 2020–2025
  1. BAY 865321, Aflibercept 8mg in RVO $773,761 470 payments
  2. A Phase 2, Double Masked, Placebo Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) $332,758 6 payments
  3. A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $328,186 180 payments
  4. BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion $243,448 154 payments
  5. A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular $192,082 82 payments
  6. Phase 2 of Ro7171009 in Ga $186,089 15 payments
  7. BAY865321, HD 8mg, AMD - Ph 3 $179,145 39 payments
  8. A Randomized, Double-Masked, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment (MR-139), in Subjects With Blepharitis $113,016 21 payments
  9. A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration $106,960 17 payments
  10. Aflibercept 8mg in RVO $88,940 84 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record